Literature DB >> 27599327

The Challenge of Latent TB Infection.

Henry M Blumberg1, Joel D Ernst2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27599327      PMCID: PMC5319563          DOI: 10.1001/jama.2016.11021

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  15 in total

1.  Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-09       Impact factor: 17.586

2.  Does prevalence matter to physicians in estimating post-test probability of disease? A randomized trial.

Authors:  Thomas Agoritsas; Delphine S Courvoisier; Christophe Combescure; Marie Deom; Thomas V Perneger
Journal:  J Gen Intern Med       Date:  2010-11-04       Impact factor: 5.128

Review 3.  Latent Mycobacterium tuberculosis infection.

Authors:  Haileyesus Getahun; Alberto Matteelli; Richard E Chaisson; Mario Raviglione
Journal:  N Engl J Med       Date:  2015-05-28       Impact factor: 91.245

4.  Leveling of Tuberculosis Incidence - United States, 2013-2015.

Authors:  Jorge L Salinas; Godwin Mindra; Maryam B Haddad; Robert Pratt; Sandy F Price; Adam J Langer
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-03-25       Impact factor: 17.586

Review 5.  Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

6.  The Prevalence of Latent Tuberculosis Infection in the United States.

Authors:  James D Mancuso; Jeffrey M Diffenderfer; Bijan J Ghassemieh; David J Horne; Tzu-Cheg Kao
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

7.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

Review 8.  Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Authors:  Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione
Journal:  Eur Respir J       Date:  2015-09-24       Impact factor: 16.671

9.  Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Linda Bauman; Karina W Davidson; John W Epling; Francisco A R García; Jessica Herzstein; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael P Pignone
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

10.  A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Authors:  Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba; Ethan Thompson; Sara Suliman; Lynn M Amon; Hassan Mahomed; Mzwandile Erasmus; Wendy Whatney; Gregory D Hussey; Deborah Abrahams; Fazlin Kafaar; Tony Hawkridge; Suzanne Verver; E Jane Hughes; Martin Ota; Jayne Sutherland; Rawleigh Howe; Hazel M Dockrell; W Henry Boom; Bonnie Thiel; Tom H M Ottenhoff; Harriet Mayanja-Kizza; Amelia C Crampin; Katrina Downing; Mark Hatherill; Joe Valvo; Smitha Shankar; Shreemanta K Parida; Stefan H E Kaufmann; Gerhard Walzl; Alan Aderem; Willem A Hanekom
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

View more
  9 in total

1.  QuantiFERON-TB Gold Versus Tuberculin Screening and Care Retention Among Persons Experiencing Homelessness: Georgia, 2015-2017.

Authors:  Jeffrey M Collins; Udodirim Onwubiko; David P Holland
Journal:  Am J Public Health       Date:  2019-05-16       Impact factor: 9.308

2.  Impact of the Ebola Virus Outbreak on Tuberculosis Treatment Adherence and Outcomes in a Military Hospital in Freetown, Sierra Leone.

Authors:  Kathryn M Hogan; Henry Saidu Bangura; Jing Li; Mohamed Akmed Salim Kamara; Jiafu Jiang; Michael E von Fricken
Journal:  Am J Trop Med Hyg       Date:  2022-03-14       Impact factor: 3.707

3.  Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.

Authors:  Kendra K Radtke; Jacqueline P Ernest; Nan Zhang; Nicole C Ammerman; Eric Nuermberger; Robert Belknap; Rosanna Boyd; Timothy R Sterling; Rada M Savic
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

4.  The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Infect Dis       Date:  2017-12-07       Impact factor: 71.421

5.  Boosting with recombinant MVA expressing M. tuberculosis α-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs.

Authors:  Prachi Nangpal; Ritika Kar Bahal; Anil K Tyagi
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

6.  Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.

Authors:  Erica L Stockbridge; Thaddeus L Miller; Erin K Carlson; Christine Ho
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

7.  The burden and predictors of latent tuberculosis infection among immigrants in South Korea: a retrospective cross-sectional study.

Authors:  Sarah Yu; Dawoon Jeong; Hongjo Choi
Journal:  BMC Infect Dis       Date:  2021-12-03       Impact factor: 3.090

8.  Combination of Blood Routine Examination and T-SPOT.TB Assay for Distinguishing Between Active Tuberculosis and Latent Tuberculosis Infection.

Authors:  Ying Luo; Guoxing Tang; Xu Yuan; Qun Lin; Liyan Mao; Huijuan Song; Ying Xue; Shiji Wu; Renren Ouyang; Hongyan Hou; Feng Wang; Ziyong Sun
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

9.  Combination of prealbumin and tuberculosis-specific antigen/phytohemagglutinin ratio for discriminating active tuberculosis from latent tuberculosis infection.

Authors:  Ying Luo; Ying Xue; Xu Yuan; Qun Lin; Guoxing Tang; Liyan Mao; Huijuan Song; Feng Wang; Ziyong Sun
Journal:  Int J Clin Pract       Date:  2020-11-27       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.